InsidersTradesSigma
LNA SANTE Stock: price and insider trades · France · AMF
Track the LNA SANTE share price and the full management transaction log of the company, a listed issuer based in France. Shares trade on FR FR, under the oversight of AMF. Operating in the Healthcare & Pharma sector, LNA SANTE has published 140 insider filings. Market capitalisation: €369.6m. The latest transaction was disclosed on 29 June 2026 (Acquisition). Among the most active insiders: SMABTP. The full history is free.
140
Insider Decl.
0
Thresholds
€51m
116 ops.
Buy Volume
€13m
7 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate LNA SANTE Strong Buy (bullish), based on 4 analysts. Average price target: €40.00.
54Σ signal
Fundamental score
Ranked 6,087 of 25,443 companies
64.8
score / 100
Value79
Quality51
FCF yld23%
Earn yld6.5%
EV/EBITDA8.3x
ROE7.7%
Gross mgn88%
Net mgn2.6%
Debt/EBITDA5.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 29 June 2026
Declarations140 total
769 shares@ €32.900.0072% mcap0.1% of flowActionEuronext Paris2026DD1123327
Ideal exit: 20 Mar 2027 (T+270)
651 shares@ €32.9940.0063% mcap0.1% of flowActionEuronext Paris2026DD1122318
Ideal exit: 15 Mar 2027 (T+270)
200 shares@ €33.000.0019% mcap0.0% of flowActionEuronext Paris2026DD1121513
Ideal exit: 9 Mar 2027 (T+270)
1,449 shares@ €33.000.014% mcap0.2% of flowActionEuronext Paris2026DD1119817
Ideal exit: 1 Mar 2027 (T+270)
856 shares@ €29.500.0083% mcap0.1% of flowActionEuronext Paris2026DD1115357
Ideal exit: 8 Feb 2027 (T+270)
233 shares@ €28.000.0020% mcap0.0% of flowActionEuronext Paris2026DD1111804
Ideal exit: 2 Jan 2027 (T+270)
2,410 shares@ €28.99540.021% mcap0.3% of flowActionEuronext Paris2026DD1110273
Ideal exit: 16 Jan 2027 (T+270)
132,373 shares@ €26.3541.14% mcap100.0% of flowActionEuronext Paris2026DD1107254
Ideal exit: 2 Jan 2027 (T+270)
132,123 shares@ €26.3511.14% mcap14.5% of flowActionEuronext Paris2026DD1105359
Ideal exit: 22 Dec 2026 (T+270)
4,333 shares0ActionEuronext Paris2026DD1092851
Ideal exit: 29 Oct 2026 (T+270)
4,333 shares0ActionEuronext Paris2026DD1092855
Ideal exit: 29 Oct 2026 (T+270)
4,333 shares0ActionEuronext Paris2026DD1092857
Ideal exit: 29 Oct 2026 (T+270)
3,450 shares@ €29.0032.5% of flowActionEuronext Paris2025DD1059134
Ideal exit: 16 Jun 2026 (T+270)
3,450 shares@ €29.0021.7% of flowActionEuronext Paris2025DD1059139
4,166 shares0ActionEuronext Paris2025DD1013158
Ideal exit: 28 Sept 2025 (T+270)
4,166 shares0ActionEuronext Paris2025DD1013142
Ideal exit: 28 Sept 2025 (T+270)
4,166 shares0ActionEuronext Paris2025DD1013155
Ideal exit: 28 Sept 2025 (T+270)
10 shares@ €22.600.0% of flowActionEuronext Paris2024DD1011788
Ideal exit: 13 Sept 2025 (T+270)
10 shares@ €22.600.0% of flowActionEuronext Paris2024DD1011790
Ideal exit: 13 Sept 2025 (T+270)
3,993 shares@ €23.99139.1% of flowActionEuronext Paris2024DD1002198
Ideal exit: 19 Jul 2025 (T+270)
6,492 shares@ €23.811814.6% of flowActionEuronext Paris2024DD1001667
Ideal exit: 14 Jul 2025 (T+270)
399 shares@ €23.82780.9% of flowActionEuronext Paris2024DD1000962
Ideal exit: 11 Jul 2025 (T+270)
24 shares@ €22.600.1% of flowActionEuronext Paris2024DD1000305
Ideal exit: 6 Jul 2025 (T+270)
102 shares@ €22.82840.2% of flowActionEuronext Paris2024DD999778
Ideal exit: 1 Jul 2025 (T+270)
2,000 shares@ €23.104.4% of flowActionEuronext Paris2024DD999287
Ideal exit: 29 Jun 2025 (T+270)
25 of 140 declarations
About LNA SANTE
LNA Santé is a French healthcare operator focused on supporting frail and dependent people, especially elderly patients and residents who require long-term care, rehabilitation or more complex medical support. Listed on the market under ISIN FR0004170017, the group was historically known as Le Noble Age before rebranding as LNA Santé in 2016 to better reflect its role as a broader healthcare platform spanning both medico-social and clinical activities. The company was founded in Nantes in 1990 by Jean-Paul Siret, who remains its Chairman and founder. Its growth started with a pioneering nursing home, La Chézalière, and then with early facilities dedicated to Alzheimer’s disease, before extending into the healthcare segment at the end of the 1990s. Today, LNA Santé operates a diversified portfolio of healthcare businesses. Its main activities include nursing homes and assisted living facilities, post-acute and rehabilitation clinics, surgical clinics, home hospitalization, mental health care and other local healthcare services. This multi-activity model allows the group to cover a wide range of patient needs across the care pathway, from accommodation and daily support to clinical treatment, rehabilitation and home-based care. The group emphasizes a human-centered model built around hospitality quality, professional caregiving, operational proximity, innovation and personalized care plans. As of 2025, LNA Santé reported 87 establishments, around 9,500 professionals and €878 million in operating revenue. It is therefore a meaningful independent player in the French healthcare landscape, although still smaller than the largest consolidated groups in the sector. Independence is a defining feature of the company’s strategy and governance. LNA Santé highlights its family ownership structure, controlled shareholding base and the increased involvement of employees, who collectively own 10% of the share capital. Geographically, the group is primarily concentrated in France, with an established presence in Belgium as well. This selective footprint is consistent with its operating model and its desire to deepen expertise rather than pursue uncontrolled expansion. LNA Santé also stands out for its long-term strategic orientation: it has become a mission-driven company and has reinforced commitments linked to social, societal and environmental performance. Among the company’s notable features are its steady expansion since inception, its recognized expertise in Alzheimer’s care, and its gradual shift toward higher-value healthcare activities with stronger medical intensity.
